Análise ultrassonográfica tardia do stent eluidor de sirolimus FirebirdTM

Background: Preliminary data have shown that the Firebird TM and the Cypher ® stents have similar safety and efficacy profiles. However, to date, no study has evaluated percutaneous coronary intervention (PCI) with the Firebird TM stent in diabetic patients. Methods: The performance of the Firebird TM stent in diabetic patients with multivessel coronary artery disease (CAD) (n = 100) was compared with that of the Cypher ® stent using historical data from the ARTS-II study (n = 159). One-year major adverse cardiovascular events (MACE) were compared. Results: Most of the patients in the Firebird TM group were male (65%), with a mean age of 63.3 ± 10.4 years, and 5% were on insulin. Stable coronary syndrome was prevalent (60%), and 45% of patients had three-vessel CAD with preserved ventricular function (56.6 ± 13.7%). In patients with three-vessel CAD, 135 lesions were treated with three or more stents in 78% of cases and with two stents in the remainder. In patients with two-vessel CAD, 110 lesions were treated with two or more stents in 80% of the cases and with one stent in the remainder. The one-year incidence of MACE with the Firebird TM stent was 21%. Mortality occurred in 3% of the patients, myocardial infarction in 2%, and a new revascularisation procedure in 18%, predominantly a new PCI (14% of cases). Comparison with the Cypher ® group did not show differences for any of the evaluated endpoints. Conclusions: In the present study, the use of the Firebird TM stent showed similar results to those of the patients in the ARTS-II study, demonstrating its suitability for use in the complex scenario of diabetic patients with multivessel CAD.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Análise ultrassonográfica tardia do stent eluidor de sirolimus FirebirdTM

Abstract: RESUMO

Cited by 3 publications

References 27 publications

Performance of the Firebird™ Drug-eluting Stent in Diabetic Patients with Multivessel Coronary Artery Disease

Performance of the Firebird™ Drug-eluting Stent in Diabetic Patients with Multivessel Coronary Artery Disease

Performance of the Firebird™ Drug-eluting Stent in Diabetic Patients with Multivessel Coronary Artery Disease

Desempenho do stent farmacológico firebird em diabéticos portadores de doença coronária multiarterial

Contact Info

Product

Resources

About

Análise ultrassonográfica tardia do stent eluidor de sirolimus FirebirdTM

Abstract: RESUMO

Cited by 3 publications

References 27 publications

Performance of the Firebird™ Drug-eluting Stent in Diabetic Patients with Multivessel Coronary Artery Disease

Performance of the Firebird™ Drug-eluting Stent in Diabetic Patients with Multivessel Coronary Artery Disease

Performance of the Firebird™ Drug-eluting Stent in Diabetic Patients with Multivessel Coronary Artery Disease

Desempenho do stent farmacológico firebird em diabéticos portadores de doença coronária multiarterial

Contact Info

Product

Resources

About

Desempenho do stent farmacológico firebird em diabéticos portadores de doença coronária multiarterial